|
|
||||||||



* Department of Materials Science and Engineering,
Department of Chemical Engineering, and the
Biological Engineering Division, Massachusetts Institute of Technology, Cambridge, MA 02139
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
However, chemotaxis need not be the only mechanism for chemokines to regulate lymphocyte motility in SLO; at uniform concentrations, chemoattractants may also increase the velocity of cell migration. The rapid, apparently randomly directed migration of T and B cells observed in vivo (1, 2, 4) could be the result of short-range direction and redirection in response to very localized chemokine gradients within the T cell and B cell areas (9), or alternatively, could represent a chemokinetic response to near-uniform levels of chemokine in the tissue. In vitro, Kaiser et al. recently reported that CCL19 secreted by mature dendritic cells (DC) stimulated pronounced motility in cocultured human naive T cells; addition of soluble CCL19 at uniform concentrations to naive T cells cultured on immature DC (which do not produce CCL19) elicited a similar induction of random motility (8). In light of the evidence, we hypothesized that chemokinesis triggered by homeostatic chemokines could be a general mechanism supporting steady-state lymphocyte motility within SLO.
Notably, in the first studies examining the effects of homeostatic chemokines on lymphocyte migration, chemokinesis was not observed (10, 11, 12). However, these in vitro studies used modified Boyden chamber assays, in which cells migrate across a thin porous membrane in response to chemoattractant; the type of migration elicited is assessed by introducing chemokine either to the culture chamber opposite the cells (to assay chemotaxis) or at equal concentrations on both sides of the membrane (for chemokinesis). The use of such "checkerboard" filterplate assays to detect and distinguish between types of migration can be problematic (13), and in some cases, factors that appeared to be only chemotactic in such assays have shown clear chemokinetic effects when more direct assays of cell migration were employed (14).
We thus used direct videomicroscopic observation to test whether the two most abundant chemokines in the T cell and B cell areas of lymph nodes and spleen, CCL21 and CXCL13, respectively, trigger chemokinesis in resting murine lymphocytes. We found that this was the case, and furthermore, in in vitro assays designed to model the relative infrequency of Ag-specific T cell-Ag-bearing DC encounters that occur during primary immune responses, we found that treatment of T-DC cocultures with CCL21 led to an early enhancement in CD69 up-regulation kinetics and a 2-fold enhancement in the number of Ag-specific T cells recovered after 4 days. These results provide a possible explanation for the lack of naive murine lymphocyte motility in purified cultures relative to their behavior in lymphoid organs and suggest that the high levels of chemokines present in SLO do not require concentration gradients to have a significant impact on lymphocyte migration.
| Materials and Methods |
|---|
|
|
|---|
All animal work was approved by the MIT Committee on Animal Care, in accordance with federal, state, and local regulations. C57BL/6, OT-II, and GFP BL/6 transgenic mice were obtained from The Jackson Laboratory. DC were derived from the bone marrow of C57BL/6 mice after the procedure of Inaba et al. (15), cultured with 5 ng/ml GM-CSF (R&D Systems), and used on day 7. CD4+ T cells were isolated from spleens or lymph nodes of 6- to 12-wk-old mice by MACS negative selection (CD4+ T cell isolation kit; Miltenyi Biotec), yielding >90% CD4+ cells, >60% CD62LhighCD44low naive T cells. For some experiments, cells were further purified: CD4+ T cells were separated into CD62L+ and CD62L fractions by MACS positive selection (CD4+CD62L+ T cell isolation kit; Miltenyi Biotec) or were sorted into CD62L+CD44low and CD62L+CD44high populations on a FACSAria (BD Biosciences). B cells isolated by MACS negative selection (B cell isolation kit; Miltenyi Biotec) were typically >85% B220+MHCII+. Cells were cultured in RPMI 1640 medium supplemented with 10% FCS, 10 mM HEPES, 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine, and 50 µM 2-ME.
Cell treatments
Cells were incubated with 110,000 ng/ml recombinant mouse CCL19 or CCL21 (R&D Systems) for 20 min before initiation of imaging to allow the chemokine to take full effect. PMA treatment (Sigma-Aldrich) was performed at 50 ng/ml, with imaging likewise initiated at 20 min. For LFA-1 blocking studies, anti-LFA-1 clone M17/4 or isotype control Ab was used; anti-I-Ab clone AF6120 was also used for B cells. For Fc block treatment, B cells were incubated with CD16/32 for 10 min on ice before the addition of other reagents. All Abs were obtained from BD Pharmingen and used at 10 µg/ml. In videomicroscopy studies utilizing pertussis toxin (PTX), cells were treated with 100 ng/ml PTX or PTX B oligomer (Sigma-Aldrich) for 10 min at 37°C, washed twice with warm medium, and rested for 90120 min before use. In coculture studies, both a high dose (100 ng/ml) and a low dose (2 ng/ml) of PTX were tested; results followed the same trends for both doses. For chemokine removal experiments, cells were washed in 10 ml of warm medium, incubated for 1 h in 2 ml of fresh medium under light shaking (<200 rpm), and washed twice more before imaging.
Videomicroscopy tracking of T cell polarization and chemokinesis
Eight-well chambered coverslips (Lab-Tek; Nalge Nunc) were incubated with 5 µg/cm2 fibronectin (FN) for 2 h at 21°C, or 10 µg/ml recombinant ICAM-1/Fc or VCAM-1/Fc fusion proteins (R&D Systems) overnight at 4°C, before addition of cells (23 x 106) and chemokine. A fraction of CD4+ T cells from C57BL/6 mouse spleens (
20%, for ease of automated tracking) were labeled with 2.5 µM fura 2-AM (Molecular Probes) for 25 min at 37°C. Similarly, splenic CD4+ T cells from GFP mice used for chemokine response longevity studies were diluted to 20% with C57BL/6 CD4+ T cells. Fura (for C57BL/6 mice, exc 380 nm, em 510 nm) or green (for GFP mice, excitation 488 nm, emission 510 nm) fluorescence and bright-field images were acquired at 30 s intervals for 40 min on a Zeiss Axiovert 200 epifluorescence microscope equipped with environmental stage (37°C, 5% CO2) with the aid of Metamorph software (Universal Imaging).
Image analysis
Cell polarization and migration were analyzed with the aid of Metamorph and Volocity (Improvision) software packages. Data were sharpened with the no-neighbors two-dimensional deconvolution algorithm in Metamorph to facilitate cell tracking using Volocity. For each field, 2644 cells were analyzed (depending on fluorescent cell density) based on intensity thresholding and size exclusion (to rid a small fraction of large cell contaminants); the dead cell population that developed during longevity experiments was excluded from analysis. A cell was scored as polarized at a single time point if its shape factor (4
area/perimeter2) did not exceed 0.85. To score average population behaviors, polarized cells were defined as those with a shape factor
0.85 in
15% of observed time points. Migrating cells were defined as polarizing cells with time-averaged velocities
4 (T cell) or 3.5 (B cell) µm/min.
T-DC cocultures
All experiments were performed in 96-well round-bottom plates (BD Falcon). To assay CD69 up-regulation, duplicate samples of 2 x 105 total cells were prepared at an overall T/DC ratio of 1:1. A portion of day 6 DC were matured with 1 µg/ml LPS (Sigma-Aldrich) and pulsed with OVA peptide (ISQAVHAAHAEINEAGR, 500 nM; AnaSpec Corporate) for 16 h, whereas others were left untouched; mixtures of peptide-loaded (and washed) mature DC (OVA-mDC) and immature DC (iDC) were then prepared at a 1:20 ratio. OT-II CD4+ T cells were also diluted 1:9 with C57BL/6 CD4+ T cells. T cells (with or without PTX pretreatment) and DC mixtures were aliquotted in FN-treated wells, briefly centrifuged (1200 rpm, 12 min), then placed in culture in the presence or absence of 1 µg/ml CCL21, which was replenished at 48 h. CD69 up-regulation was analyzed at times ranging from 24 to 96 h: duplicate samples were pooled, cells were stained with anti-CD69-FITC, anti-V
2-PE, and anti-CD4-biotin followed by streptavidin-allophycocyanin, and finally propidium iodide.
The effect of CCL21 on T cell proliferation was assessed by a CFSE dilution assay, using a similar coculture system: OT-II T cells were labeled with 10 µM CFSE for 10 min and washed 3x before mixing with C57BL/6 CD4+ T cells at a 1:9 ratio. Triplicate cocultures of 5 x 105 total cells were prepared at an overall T/DC ratio of 9:1 and an iDC/OVA-mDC ratio of 1:1; 1 µg/ml CCL21 was added at time zero to CCL21-treated cultures. Proliferation in each well was assayed on day 4 by flow cytometry analysis of cultures stained with anti-V
2-PE, anti-V
5-biotin (then streptavidin-allophycocyanin), and propidium iodide. All data was collected on a FACSCalibur (BD Biosciences) using CellQuest software and analyzed with FlowJo software, using Abs obtained from BD Pharmingen.
| Results |
|---|
|
|
|---|
Many chemokines, including CCL19 and CCL21, are known to trigger polarization in resting T cells at uniform concentrations (16, 17). We confirmed that both CCL21 (Fig. 1, A and B) and CCL19 (data not shown) elicited pronounced polarization of
75% of freshly isolated murine (C57BL/6 strain) CD4+ T cells within 5 min, whereas the majority of untreated resting cells were round. In experiments where CD62L+CD44low, CD62L+CD44high, and CD62LCD4 T cells were separated, all populations responded nearly equally to CCL21 (data not shown). When T cells were seeded on bare glass with soluble CCL21 and tracked by videomicroscopy, we observed not only rapid cell polarization, but also that a small fraction of cells (
3%) appeared to actively migrate (Fig. 1B). Because polarization and adhesion are two prerequisites for T cell motility (6, 18), and CCL21 is known to induce adhesion to integrin ligands (19, 20), we tested whether motility would follow polarization if the cells were exposed to a suitable adhesive substrate.
|
v
= 5.16 ± 2.08 µm/min) was likewise significantly higher (p
0.0001) than that observed for cells on ICAM-1 with no chemokine (Fig. 1F).
Importantly, chemokinetic migration was dependent on the presence of both chemokine and adhesive ligand: when the T cell integrin LFA-1 was blocked with an Ab, T cells on ICAM-1 substrates polarized, but failed to migrate (Fig. 1G); isotype control Ab had no effect (data not shown). Treatment of T cells with PTX, which inhibits G-protein-coupled receptor signaling, reduced both polarization and migration (p
0.05), whereas the PTX B oligomer (control) had no effect (Fig. 1G). Blocking LFA-1-ICAM-1 interactions with an anti-LFA-1 Ab or treating the cells with PTX significantly reduced average cell velocities as well (Fig. 1F). We tested whether the observed migration was a result primarily of increased adhesion to ICAM-1 rather than chemokinesis per se, by treating cells with the phorbol ester PMA, which increases T cell adhesion to ICAM-1 (21). PMA triggered polarization in a majority of cells, but did not induce migration on ICAM-1 (Fig. 1G). Thus, CCL21 elicits chemokinesis from CD4+ T cells, with migration dependent upon G-protein-coupled receptor signaling and exposure to an adhesive substrate such as ICAM-1.
Chemokinesis occurs at physiological CCL21 doses and supports long-lived cell migration
Naive T cells are estimated to spend 1218 h in a single lymph node during their homeostatic recirculation between blood and secondary lymphoid tissues (9). For chemokinesis triggered by CCL21 to be relevant to T cells search for Ag in lymph nodes, the migratory response would need to be sustained throughout a similar time period in response to chemokine doses present in the intact tissues. The concentration of CCL21 in SLO has been estimated at
2 and
10 µg/ml by ELISA and Western blotting of tissue supernatants, respectively (22, 23, 24). Using videomicroscopy, we found an onset of T cell motility induced by 10100 ng/ml CCL21, whereas the percentage of cells polarizing and migrating began to plateau between 100 and 1000 ng/ml (Fig. 2A). However, the average time that any particular cell spent polarized and the average single-cell velocity continued to increase up to at least 10 µg/ml (data not shown). Notably, the onset and plateau response in chemokinetic migration measured here parallels the dose response reported for chemotactic migration triggered by murine CCL21 (25).
|
0.0001; Fig. 2C). Thus, CCL21-driven responses are sustained at physiological concentrations over time periods consistent with lymphocyte residence in a given lymph node and appear to be dependent on the persistent presence of chemokine. CCL21 triggers chemokinesis on several adhesion ligands present in secondary lymphoid tissues
To determine whether CCL21 could synergize with other adhesion ligands present within T cell areas of SLO to promote T cell migration, we observed CD4+ T cell motility on VCAM-1 and FN-coated substrates for comparison to the response observed on ICAM-1 surfaces. T cell polarization induced by CCL21 was statistically identical on bare glass or in the presence of each adhesion ligand (Fig. 3A). For all four surfaces, the population time-averaged velocity was increased in the presence of CCL21 (Fig. 3B). (This was true even on bare glass where cells were non-adherent, due to increased convection caused by CCL21-induced polarization.) However, the CCL21-induced increase in mean velocity of T cells was significantly greater for cells cultured on ICAM-1, VCAM-1, and FN compared with bare glass, suggesting that CCL21 can synergize with multiple adhesion ligands to promote T cell migration (Fig. 3B; p
0.05). The exact velocity profiles of both chemokine-treated and untreated cells depended on the surface (Fig. 3C); this is to be expected, because cell migration rates are controlled by adhesion strengthwhich likely differs for each ligand at the single surface-coating densities tested hereas well as potential qualitative differences in the adhesion receptors involved (26). However, the responses measured here clearly indicate that chemokinesis induced by CCL21 in concert with an adhesive substrate is not limited to synergy with ICAM-1 alone.
|
To determine whether CCL21 could impact naive T cell priming under conditions modeling the rarity of Ag-specific encounters in vivo, we prepared T cell-DC cocultures where both Ag-specific T cells and peptide-bearing DCs were present at high dilution. We first assayed T cell activation kinetics via CD69 up-regulation, reasoning that chemokinesis triggered by CCL21 might alter the rate of early priming events. Peptide-loaded mature bone marrow-derived DCs (OVA-mDC) were mixed with peptide-free iDC at a ratio of 1:20 and plated in FN-coated round-bottom culture wells. A mixture of OVA peptide-specific transgenic CD4+ T cells (OT-II) (27) and CD4+ T cells from wild-type (C57BL/6) mice (at a 1:9 ratio) was then added for an overall 1:1 T/DC ratio. Wells received CCL21 (1 µg/ml) at both 0 and 48 h or were left untreated, and CD69 up-regulation was assessed as a function of time on equal numbers of live Ag-specific cells (identified as CD4+V
2+PIlow cells, a gating that included some wild-type cells) (Fig. 4A). As shown in Fig. 4B for a representative experiment, the fraction of CD69high V
2+ cells was higher for CCL21-treated samples than for untreated controls at all time points, by up to 1.5-fold at 48 h.
|
0.05; Fig. 4C) and was most prominent at 48 h.
To examine the end-point effects of CCL21 on T cell priming, we performed a CFSE dilution assay to directly observe Ag-specific cell division. For this assay, OT-II T cells were again diluted 1:9 with polyclonal CD4+ T cells, but a more physiological total T/DC ratio of 9:1 was used, and the DC population was equal parts iDC and OVA-mDC. OT-II T cells in the culture were labeled with CFSE to track cell division by flow cytometry. At 85 h, equal volumes of total cells were analyzed, and the number of live OT-II cells (V
2+V
5+PIlow) and their CFSE fluorescence distribution were determined. In control cocultures where all DCs were immature cells lacking Ag, no cell division was observed; in contrast, both PTX-treated and untreated OT-II cells proliferated when OVA-mDC were present (Fig. 5A and data not shown), with similar cell division profiles irrespective of CCL21 treatment (2.88 ± 0.03 vs 2.70 ± 0.02 mean divisions per cell in the presence or absence of chemokine, respectively, for the OVA-mDC case). Equal numbers of OT-II cells were recovered from PTX-treated samples regardless of CCL21 treatment (Fig. 5B). However, in both the presence and absence of OVA-mDC, the addition of CCL21 increased the number of OT-II T cells recovered significantly, by 2.0- and 1.4-fold, respectively (p
0.05; Fig. 5B). In comparing multiple similar experiments, we found that the fold increase in T cell recovery was consistently greater in the presence of Ag-bearing DCs than in their absence (2.1 ± 0.4-fold in the presence of Ag, 1.4 ± 0.1-fold in the absence of Ag, p
0.05), thus showing an Ag-specific effect. The enhanced cell recovery in CCL21-treated cocultures was not due to a direct survival signal delivered to resting T cells by chemokine, as purified T cells cultured alone for 24 h with or without CCL21 were recovered in equal numbers (data not shown). Altogether, these results suggest that CCL21 signaling can impact the kinetics of early activation events and the ultimate number of expanded T cells while having a minor impact on the mean number of cell divisions, under conditions where Ag-specific T cells and peptide-bearing DCs are present at low frequency.
|
The data presented above show strong chemokinesis induced in CD4+ T cells by CCL21, a chemokine produced constitutively at high levels in the T cell areas of SLO (9). To determine whether chemokinesis is also a potential regulatory mechanism in B cell areas of SLO, we tested whether CXCL13, produced constitutively in follicles, would elicit an analogous response in B lymphocytes. B cells isolated from C57BL/6 mice were seeded on ICAM-1-coated substrates with or without CXCL13 and tracked by videomicroscopy as above. Like CD4+ T cells, B cells displayed low motility on ICAM-1 surfaces, but cell polarization and migration increased dramatically on exposure to CXCL13 (
v
= 4.10 ± 1.58 µm/min) (Fig. 6A). PTX treatment blocked this response to CXCL13 completely, whereas treatment of cells with PTX B oligomer had almost no effect. Analogous to T cells, treatment with the nonspecific adhesion stimulus PMA caused polarization but did not induce migration. However, in contrast to T cell responses to CCL21, anti-LFA-1 treatment suppressed both CXCL13-induced migration and polarization. To rule out potential nonspecific effects of coating the cells with the blocking Ab or FcR signaling in the cells, we also compared the response of cells treated with an isotype-matched anti-I-Ab (Fig. 6A); in this case B cell polarization and migration was not statistically different from untreated cells. (A non-binding isotype control Ab also failed to block CXCL13 responses; data not shown). These results suggest that in B cells, both polarization and migration on ICAM-1 are governed by a synergy between chemokine and LFA-1 signaling. Little movement of B cells from their point of origin was observed on ICAM-1 in the absence of chemokine, but single cell tracks revealed significant random motility upon addition of CXCL13, with peak instantaneous velocities >15 µm/min and average velocities of 4.10 ± 1.58 µm/min (Fig. 6, B and C). Thus, B cells respond to synergistic signaling from CXCL13 and ICAM-1 and exhibit chemokinetic migration in a manner largely analogous to the response of T cells to CCL21 and ICAM-1.
|
| Discussion |
|---|
|
|
|---|
We first showed, using direct videomicroscopic observation, that the homeostatic chemokine most abundant in T cell areas of SLOCCL21causes pronounced T cell migration in the absence of specific gradients and that this response is critically dependent on the presence of appropriate ligands to promote cell adhesion, notably ICAM-1. In secondary lymphoid tissues where CCL21 (and CCL19) is constitutively produced, T cells are exposed to VCAM-1 on stromal cells and DCs (33), ICAM-1 on DCs (34) and potentially stromal cells (33), and possibly FN presented by fibroblastic reticular cells or exposed on the surface of a small fraction of reticular fibers not enveloped by reticular cells (35, 36). We found that all three of these ligands could support some degree of cell migration. Highly favorable T cell migration on ICAM-1 may reflect the need for rapid investigation of DC cell bodies. Notably, histological studies reveal that
60% of T cells in lymph nodes are in contact with DCs at any given moment (31).
For chemokinesis to be relevant for T cell migration within SLO, it should be sustained for the typical cell residence time: 1218 h in the case of lymph nodes (9). We found that CCL21-induced chemokinesis is indeed sustained for at least 24 h, consistent with the finding in the human system that, in contrast to many chemokine/receptor interactions, CCL21 binding to CCR7 does not trigger receptor down-modulation (37). The residual cell polarization we observed after washing out chemokine may be due to the high-affinity nature of CCL21-CCR7 binding and possible chemokine sequestration by cell surface proteoglycans (38, 39), which complicate full separation of the cells from ligand. Nevertheless, we observed that the long-term chemokinetic response was dependent at least in part on the continued presence of CCL21.
Based on these findings, we sought to examine whether chemokinesis triggered by CCL21 could impact T cell priming, using a culture system designed to model the infrequency of Ag-specific T-DC contacts in vivo. We found that addition of CCL21 to T cell-DC cocultures enhanced the initial kinetics of CD69 up-regulation and led to 2-fold greater numbers of Ag-specific OT-II T cells recovered after 4 days. Because activated/expanded T cells are constitutively motile (40, 41, 42, 43), we might expect that the presence of CCL21 would only alter the initial number of (otherwise non-motile) naive T cells that would encounter a DC and begin proliferating. Naive cells that did make contact with DCs and divide (in the presence or absence of chemokine) would thus proceed at equal rates to begin dividing, assuming equal rates of further cell division and no differences in cell death (we found similar fractions of apoptotic cells in cultures with or without CCL21, data not shown). In agreement with this hypothesis, CCL21-treated T cells had similar cell division profiles as control cellsonly the recovery of Ag-specific T cells changed. Surprisingly, we found that addition of CCL21 to peptide-free cocultures also increased the recovery of OT-II cells, though control experiments revealed no evidence for a direct survival signal given to T cells by CCL21 (data not shown). This could be due to CCL21-driven T cell motility increasing Ag-independent T-DC contacts, which promote T cell survival (44, 45). We found that the increase in T cell recovery was consistently greater in the presence of Ag-bearing DCs than in their absence, suggesting an Ag-specific effect apart from survival cues imparted to T cells by immature DCs.
These results suggested an influence of T cell chemokinesis on priming but were not definitive, since the receptor for CCL21, CCR7, is expressed by both naive T cells and mature DCs (46), and CCR7 signaling is known to promote DC motility (47), dendrite extension (48), and enhance LPS-driven maturation (49). However, flow cytometry analysis of our LPS-matured DCs exposed to the prokaryotic-derived CCL21 used here showed no evidence of further maturation, nor were immature DCs matured by CCL21 (data not shown). More importantly, selective PTX treatment of T cells alone largely abrogated the positive effects of CCL21 (Figs. 4, B and C, and 5B), suggesting that chemokine receptor signaling in T cells was responsible for the accelerated CD69 up-regulation and enhanced proliferation of Ag-specific cells in our coculture system. Notably, CD69 up-regulation and proliferation of PTX-treated cells were slightly lower than for untreated T cells even in the absence of exogenously added CCL21 (Figs. 4, B and C, and 5B), perhaps reflecting a contribution of other chemokine signals to the T cell responsee.g., CCL19, which is produced by mature DCs (50) and which has recently been shown by Kaiser et al. to promote T cell scanning of DCs (8).
Finally, we examined whether B lymphocytes exposed to the follicular homeostatic chemokine CXCL13 would have a chemokinetic response analogous to T cells. B cells on ICAM-1 surfaces were indeed stimulated to migrate by CXCL13. Consistent with the slower velocities of B cells relative to T cells reported by imaging of intact lymphoid tissues (2, 51), the population average velocity and peak velocities of single cells were lower for B cells treated with CXCL13 than for CD4+ T cells responding to CCL21.
Altogether, these findings suggest that the rapid migration of lymphocytes observed within the parenchyma of SLO could be supported by chemokine signaling in the absence of significant concentration gradients. Recent analyses of T cell migration within intact SLO have so far failed to reveal evidence for chemotaxis during homeostatic lymphocyte trafficking once T and B cells reach their respective zones, which may reflect a truly random program for T cell scanning or the action of very local attraction gradients near APCs (1, 2, 4). In either case, the data shown here suggest that homeostatic chemokines could function not only to direct lymphocytes to their respective compartments but also to regulate the random motility of these cells in lymphoid organs observed during their constitutive surveillance for Ag.
| Acknowledgments |
|---|
| Disclosures |
|---|
|
|
|---|
| Footnotes |
|---|
1 This work was supported by the Whitaker Foundation (Grant no. RG-02-0837) and Defense Advanced Research Planning Agency (award W81XWH-04-C-0139). ![]()
2 Address correspondence and reprint requests to Dr. Darrell J. Irvine, Massachusetts Institute of Technology, Room 8-425, 77 Massachusetts Avenue, Cambridge, MA 02139. E-mail address: djirvine{at}mit.edu ![]()
3 Abbreviations used in this paper: SLO, secondary lymphoid organs; DC, dendritic cell; FN, fibronectin; iDC, immature DC; OVA-mDC peptide-bearing mature DC; PTX, pertussis toxin. ![]()
Received for publication November 22, 2005. Accepted for publication May 25, 2006.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
K. Gollmer, F. Asperti-Boursin, Y. Tanaka, K. Okkenhaug, B. Vanhaesebroeck, J. R. Peterson, Y. Fukui, E. Donnadieu, and J. V. Stein CCL21 mediates CD4+ T-cell costimulation via a DOCK2/Rac-dependent pathway Blood, July 16, 2009; 114(3): 580 - 588. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Britschgi, A. Link, T. K. A. Lissandrin, and S. A. Luther Dynamic Modulation of CCR7 Expression and Function on Naive T Lymphocytes In Vivo J. Immunol., December 1, 2008; 181(11): 7681 - 7688. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Zheng, B. Jin, S. E. Henrickson, A. S. Perelson, U. H. von Andrian, and A. K. Chakraborty How Antigen Quantity and Quality Determine T-Cell Decisions in Lymphoid Tissue Mol. Cell. Biol., June 15, 2008; 28(12): 4040 - 4051. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Miles, E. Liaskou, B. Eksteen, P. F. Lalor, and D. H. Adams CCL25 and CCL28 promote {alpha}4{beta}7-integrin-dependent adhesion of lymphocytes to MAdCAM-1 under shear flow Am J Physiol Gastrointest Liver Physiol, May 1, 2008; 294(5): G1257 - G1267. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Barone, M. Bombardieri, M. M. Rosado, P. R. Morgan, S. J. Challacombe, S. De Vita, R. Carsetti, J. Spencer, G. Valesini, and C. Pitzalis CXCL13, CCL21, and CXCL12 Expression in Salivary Glands of Patients with Sjogren's Syndrome and MALT Lymphoma: Association with Reactive and Malignant Areas of Lymphoid Organization J. Immunol., April 1, 2008; 180(7): 5130 - 5140. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Huang, L. I. Cardenas-Navia, C. C. Caldwell, T. J. Plumb, C. G. Radu, P. N. Rocha, T. Wilder, J. S. Bromberg, B. N. Cronstein, M. Sitkovsky, et al. Requirements for T Lymphocyte Migration in Explanted Lymph Nodes J. Immunol., June 15, 2007; 178(12): 7747 - 7755. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Worbs, T. R. Mempel, J. Bolter, U. H. von Andrian, and R. Forster CCR7 ligands stimulate the intranodal motility of T lymphocytes in vivo J. Exp. Med., March 19, 2007; 204(3): 489 - 495. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Nombela-Arrieta, T. R. Mempel, S. F. Soriano, I. Mazo, M. P. Wymann, E. Hirsch, C. Martinez-A., Y. Fukui, U. H. von Andrian, and J. V. Stein A central role for DOCK2 during interstitial lymphocyte motility and sphingosine-1-phosphate-mediated egress J. Exp. Med., March 19, 2007; 204(3): 497 - 510. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Okada and J. G. Cyster CC Chemokine Receptor 7 Contributes to Gi-Dependent T Cell Motility in the Lymph Node J. Immunol., March 1, 2007; 178(5): 2973 - 2978. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |